Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
14,296 people get ABT articles and Market Currents by email alert.
Get email alerts on ABT »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
-
-
-
At These Levels, Covidien Has Room To RunStephen Barnes • Tue, Apr 30 -
-
-
-
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
Abbott Hopes Mitral Repair Will Be The New TAVIEP Vantage • Wed, Feb 27 -
-
-
-
-
-
-
-
Abbott Earnings Preview: What We Are WatchingTrefis • Tue, Jan 22
-
-
-
-
-
-
-
-
-
-
-
-
At These Levels, Covidien Has Room To RunStephen Barnes • Tue, Apr 30
-
-
-
-
-
-
-
-
-
-
Abbott Laboratories' Management Presents HCV Program Update (Transcript)Mon, Nov 12, 2012
-
Abbott Laboratories Q1 2010 Earnings Call TranscriptWed, Apr 21, 2010
-
Abbott Laboratories Q4 2009 Earnings Call TranscriptWed, Jan 27, 2010
-
Abbott Laboratories, Q3 2009 Earnings Call TranscriptWed, Oct 14, 2009
-
Abbott Laboratories, Q2 2009 Earnings Call TranscriptWed, Jul 15, 2009 • 1 Comment
-
Abbott Laboratories Q1 2009 Earnings Call TranscriptFri, Apr 17, 2009
-
Abbott Laboratories Q4 2008 Earnings Call TranscriptWed, Jan 21, 2009
-
at CNBC.com (Fri, 6:29PM)
-
at CNBC.com (Fri, 6:02PM)
-
at CNBC.com (May 13, 2013)
-
at MarketWatch.com (Apr 30, 2013)
-
at CNBC.com (Apr 29, 2013)
-
at CNBC.com (Apr 22, 2013)
-
at MarketWatch.com (Apr 17, 2013)
-
at MarketWatch.com (Apr 17, 2013)
-
at MarketWatch.com (Apr 17, 2013)
-
at CNBC.com (Apr 17, 2013)
-
at MarketWatch.com (Apr 16, 2013)
-
at CNBC.com (Apr 14, 2013)
-
at CNBC.com (Apr 3, 2013)
-
at CNBC.com (Apr 2, 2013)
-
at MarketWatch.com (Mar 22, 2013)
-
at CNBC.com (Mar 20, 2013)
-
at CNBC.com (Mar 11, 2013)
-
at CNBC.com (Feb 14, 2013)
-
at MarketWatch.com (Jan 30, 2013)
-
at MarketWatch.com (Jan 23, 2013)
ABT vs. ETF Alternatives
Company Description
Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott's* principal business is the discovery, development, manufacture, and sale of a broad and diversified line of health care products.
Abbott has four reportable revenue segments: Pharmaceutical Products, Diagnostic... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, June 4, 2012, 11:48 AM Abbott Labs (ABT -0.4%) opens its first nutrition R&D center in India, which, with widespread malnutrition and the largest diabetes population in the world, is "a growth area" for the company. Abbot will therefore explore manufacturing nutrition products and boosting its sales and distribution ops in the country. 1 Comment [Healthcare]
- Monday, May 7, 2012, 12:56 PM Abbott Labs (ABT -0.1%) reaches an $800M settlement with the government to resolve all outstanding issues regarding an investigation of past sales and marketing practices relating to its neurologic medication Depakote. The settlement stems from a four-year-old investigation into past sales activities, dating as far back as 1998. Additionally, the pharmaceutical giant says it will split into two separately traded companies. Comment! [Healthcare, Breaking News]
- Tuesday, April 24, 2012, 6:20 AM Nestle (NSRGY.PK) may sell $1.2B-$1.8B worth of assets from the infant-nutrition unit that it's buying from Pfizer for $11.85B in order to allay antitrust concerns in countries around the world, Bloomberg reports. Potential suitors could include Heinz (HNZ), Abbot Labs (ABT) and P-E funds. Comment! [Consumer]
- Wednesday, April 18, 2012, 7:59 AM More on Abbott Laboratories' (ABT) Q1: Segment revenue gains led by Proprietary Pharmaceuticals (+6.6%), Nutritionals (+11%), and Core Laboratory Diagnostics (+12.8%). Says it's on track to separate into two companies by year end. Raises its outlook for full-year 2012 EPS to $5.00-$5.10, from prior guidance of $4.95-$5.05. Shares +1.3% premarket. (PR) Comment! [Earnings]
- Wednesday, April 18, 2012, 7:47 AM Abbott Laboratories (ABT): Q1 EPS of $1.03 beats by $0.03. Revenue of $9.46B (+4.6% Y/Y) beats by $90M. (PR) Comment! [Earnings, Healthcare]
- Wednesday, April 18, 2012, 12:05 AM Notable earnings before Wednesday's open: ABT, AMLN, ASML, BK, HAL, HBAN, NYB, PNC, STJ, TXT Comment! [Earnings]
- Tuesday, April 17, 2012, 5:30 PM Notable earnings before Wednesday's open: ABT, AMLN, ASML, BK, HAL, HBAN, NYB, PNC, STJ, TXT Comment! [Earnings]
- Tuesday, April 17, 2012, 4:10 PM Abbott Labs (ABT) says the results from its Phase 3 trial evaluating levodopa-carbidopa intestinal gel, its investigational compound for advanced Parkinson's disease, showed that patients reported clinically meaningful and statistically significant improvements compared to levodopa-carbidopa immediate release tablets. Comment! [Healthcare]
- Wednesday, April 11, 2012, 12:34 PM Abbott Laboratories' (ABT +0.4%) top-selling arthritis drug Humira is approved in Europe for moderate to severe ulcerative colitis. The decision makes Humira the first and only self-injectable biologic therapy for ulcerative colitis, and marks the seventh indication for the therapy in the EU since the product's first approval in 2003. 1 Comment [Healthcare]
- Wednesday, April 4, 2012, 12:48 PM Shares of Idenix Pharmaceuticals (IDIX -12.2%) sink after Abbott Laboratories (ABT +0.6%) releases positive results from studies of its experimental hepatitis C treatment. Other Hep-C companies vying for a piece of the rapidly-growing multi-billion dollar market: Gilead Sciences (GILD -2.2%), Vertex Pharmaceuticals (VRTX -1.2%), Bristol-Myers Squibb (BMY -0.5%), BioCryst Pharmaceuticals (BCRX -3.4%). 1 Comment [On the Move, Healthcare]
- Wednesday, April 4, 2012, 12:36 PM Abbott Laboratories (ABT +0.5%) announces that studies of its experimental hepatitis C drug showed it suppressed the virus in most patients. If further studies follow through with positive results, the company plans to launch a new hepatitis C regimen in 2015. Comment! [Healthcare]
- Wednesday, March 28, 2012, 6:23 PM Myriad Genetics (MYGN) signs an agreement with Cephalon, a subsidiary of Teva Pharmaceutical (TEVA), to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase I/II clinical study. Myriad has entered into similar agreements with Abbott (ABT), Astra Zeneca (AZN) and BioMarin (BMRN) to provide similar diagnostic testing. Comment! [Healthcare]
- Tuesday, March 27, 2012, 10:00 AM The upcoming division of Abbott Laboratories (ABT +0.4%) into two companies will lead to a run on shares prior to the split, according to John Mylant. He sees investors getting drawn in by the combination of catching an income producer (Abbvie) and a growth stock (Abbott) with one trade. 1 Comment [Healthcare, Quick Ideas]
- Wednesday, March 21, 2012, 10:07 AM Abbott Laboratories (ABT -0.3%) announces a new research pharmaceutical company that it expects to launch by the end of FY12 as part of its previously announced split. Called AbbVie, the new company will include Abbott's current portfolio of proprietary pharmaceuticals and biologics. The medical products company company will keep the Abbott name. Comment! [Healthcare]
- Tuesday, March 20, 2012, 12:08 PM The Supreme Court's decision to reject Prometheus Labs' (NSRGY.PK) testing patents has wider industry implications and could be a setback for other biotechs that sell diagnostic devices, including Roche (RHHBY.PK), Abbot (ABT +0.3%) and Myriad Genetics (MYGN -5.4%) Comment! [Healthcare]
- Monday, March 19, 2012, 3:14 PM Abbott Labs (ABT +1.4%) hits a three-year high as Deutsche Bank hikes its rating to Buy, arguing shares should climb ahead of the planned split of ABT’s drug unit from the rest of the company. Pharma could be worth $36/share by year-end 2012, the firm says, while the faster-growing medical products business could carry a value of $31/share. Comment! [Healthcare, On the Move]
-
- View all 1 replies
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
-
- View all 0 replies
-
The Wall Street Transcript
Regulatory & Macro Clarity Stabilize Revenue, Earnings in Biotech; Analyst Discusses $ABT, $AMGN, $CELG, $GILD- http://su.pr/9MGqka - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
Michael Bryant
Pepsi (PEP), Abbott (ABT), Johnson Controls (JCI), and Ford (F) are great companies and investments, but don't expect +20% annual yields. - View all 3 replies
-
-
-
- View all 7 replies
-
-
